Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It’s really hard to do when you open your account and see negative $$. I’ve already disposed of some. I was hoping for something, anything of hope to get completely out.
I think 10 years is pretty resilient and I am smart. The only thing left that keeps me here is the CEO is holding a larger bag.
A learning experience indeed.
Yup, life is too short and I wish I could take such a devastating loss from selling. I can’t do that, nor can many others here. It’s easy to say that to someone if you have a cushion Dr.
Forgot the word “cheap” and I am fully aware of what I unfortunately own. Just want my $$ back. Not selling till I do, which again unfortunately seems like not anytime soon. Rah Rah...drop the pompoms
As much as I want all you cheerleaders to be right, my money has been tied up in speculation for 10 years. Now granted it does take that long for a pharmaceutical company to be successful but a little transparency goes a very long way. I invested in Sequestox being born. Yeah, I know adderall Yada Yada Yada new CNS, but geez, drop us a few breadcrumbs or all we are is a cheap generic company.
I would love my initial investment back. Don’t see that happening after this. It’s not a good sign when a CFO leaves. Some even say it’s worse than a CEO leaves.
Agree..things are not looking up
If he sells his shares , I’m out. Why would he sell if all this “great revenue” was continued. Some one said Plassche was leaving in June. WTF is going on. We need transparency NOW. According to the 8k, he’s being replaced and they are searching. This does not bode well when a CFO leaves.
If he opened up questions on CC, I’d love to hear him skate around that question and MANY more. He’s controlling all of us. It gives me flashbacks of CTIC...what a clusterduck that was.
More like a KO...no champ loses 50%
Nasrat has so much invested, but also with Mikah. How can the whole thing can even be legal. Playing on both sides of the fence. No offense to any attorneys on here, but they are crafty about making money..for themselves.
It would take an act of god to get this stock to move up. Unfortunately he’s a bit busy welcoming everyone at the gates. So much loss everywhere you turn. God bless us all.
It’s like a tragic accident...I don’t want to watch
I have held this stock since 2010-11, Je, I am starting to agree with you. Every time I look at my account I am now getting mad. No excuse for this anymore.
I respect everyone’s opinion but, c’mon this is ridiculous how low it’s going. Nasdaq, your always always “loading up” ....how much are you dumping back. Not being disrespectful. Just so exhausted with this stock. I know, just sell and move on...Yada Yada Yada...kind of difficult to flush that huge red loss.
Had to vent..apologies to any offended
Can’t disagree with this comment. Same games played on the big boards as well. But sure would love some institutions buying in. I love me a good Western, but the otc boards are brutal.
I just got off the call. Nothing bad at all. He’s playing everything safe and clinical trials starting soon for CNS drug. Lapree brought on for this job. Long term it’s good short term players should move on.
I’m long term and super red...I’ll wait. Nasdaq uplist mentioned, but every criteria met, but share price ( my assumption) That said, it means one thing...split after CNS announcement. Give you a great pr then drop the bomb. I know it’s the same...Yada, Yada, yada but nobody likes a reverse split period.
Same lousy music...waiting to start call
I predict merger news
Agree with your post. Tip of the iceberg
If one is interested, there may be a bidding war. Here’s hoping, go big or go home.
Not saying it’s them, but article intriguing
BLOOMBERG
Canopy Growth Corp., the world’s most valuable marijuana company, is making a big bet on the U.S. market.
Canopy, which was sitting on a pile of cash after a high-profile investment last year from alcohol giant Constellation Brands Inc., has agreed to buy New York-based Acreage Holdings Inc. for $3.4 billion in a cross-border deal that may usher in a wave of consolidation in the burgeoning cannabis industry.
But for Canopy, there’s one major contingency: The deal by the Canadian firm hinges on the U.S. legalizing weed at the federal level, a thorny political issue that is by no means assured.
So far, Canada has been at the center of banking and merger activity in the marijuana business because the drug is federally legal there. But the U.S. market in legal pot is already bigger than Canada’s, despite federal prohibition south of the border. That has put pressure on the Canadian companies to find a way into the American market, according to Ken Shea, an analyst at Bloomberg Intelligence.
“They know the U.S. is the biggest prize of all,” he said.
Absolutely hold. You’ll see the price rise towards end of day, leading into 3 day weekend. Would be great to announce on Tuesday morning a formal buyout.
Per the Securities and Exchange Commission: “Academic studies find that OTC stocks tend to be highly illiquid; are frequent targets of alleged market manipulation; generate negative and volatile investment returns on average; and rarely grow into a large company or transition to listing on a stock exchange.”
To be clear, this is not to say that every penny stock or OTC company is a scam. The danger is that the over-the-counter market is where the scam stocks live. Think of it as a bad neighborhood. Being there can make you a mark for a con.
Just saying
Now for the game...Go Bucs!
It’s time for a little magic for us mushrooms. Just watched the show Ray Donovan and fell in love with his cars. I need an upgrade.
Elite owes their shareholders some green. It’s been long enough.
Got it. I see they are up and running again. Here’s hoping for some great news soon.
Why would that be...Bezos a shareholder. Wish he would promote it.
Elon Musk References ‘Signal,’ Causes Wrong Stock to Surge 1100%
I’m sad to say I’ve been one for way too long. So underwater, I’ve sprouted gills. Hoping for just my initial investment back at this point. Making some $$ on GPFT.
Could be server, hopefully nothing nefarious.
I just confirmed it’s down online, so I know it’s internal on their end. It was down yesterday as well.
Elite website Down for a while now.
Just checked a few sites and both say server down.
2014
Dr. LePree joins Elite with a wealth of experience in formulations and analytical research and development having most recently served as the Principal Scientist, Formulations Research and Development for Capsugel. Dr. LePree also held previous positions in research and development with Abon Pharmaceuticals, Penwest Pharmaceuticals, Novartis, and Hoffman-LaRoche. Dr. LePree has a B.S. in Pharmacy from Rutgers University and a Ph.D. in Pharmacy from the University of Wisconsin. He is also an Adjunct Professor of Pharmacy at Long Island University.
2020
Dr. LePree has over 20 years of pharmaceutical development experience in small, mid-sized, and large branded and generic pharmaceutical companies including scientific leadership positions at Ferring International Pharmaceutical Science Center - US, Gattefossé Corporation, Novartis, and Capsugel. Dr. LePree received his B.S. degree in Pharmacy from Rutgers University and his Doctor of Philosophy degree in Pharmacy (Pharmaceutics) with a minor in Chemistry from the University of Wisconsin-Madison. Dr. LePree has experience in Formulation Development, Materials Characterization, and Analytical Sciences.
Not new.
2014
ELITE PHARMACEUTICALS ANNOUNCES NEW MANAGEMENT APPOINTMENTS
NORTHVALE, N.J. – October 24, 2014 – Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, today announced key management appointments of Dr. Kenneth Smith, J.D., M.B.A., as Vice President of Legal, Dr. Jason LePree as Vice President of Scientific Affairs and Dr. Sophy Abraham as Head of Regulatory Affairs.
Dr. Smith previously held the positions of Chief Intellectual Property Counsel for Alpharma, Inc. and before that Head of North American Intellectual Property for Sanofi Aventis. In both positions, Dr. Smith had global responsibility for all intellectual property issues related to multiple business units involved with various technologies including branded products, animal health products, active pharmaceutical ingredients, generic drugs, and vaccines. Dr. Smith also brings extensive background and knowledge in the area of abuse deterrent intellectual property. Dr. Smith has a Ph.D. in Biochemistry from University of Houston, an M.B.A from Lehigh University, and a J.D. from the University of Houston.
Dr. LePree joins Elite with a wealth of experience in formulations and analytical research and development having most recently served as the Principal Scientist, Formulations Research and Development for Capsugel. Dr. LePree also held previous positions in research and development with Abon Pharmaceuticals, Penwest Pharmaceuticals, Novartis, and Hoffman-LaRoche. Dr. LePree has a B.S. in Pharmacy from Rutgers University and a Ph.D. in Pharmacy from the University of Wisconsin. He is also an Adjunct Professor of Pharmacy at Long Island University.